Alembic Pharmaceuticals Limited (BOM:533573)

Alembic Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	834.8	1,202	754.8	610.9	980.6
Trading Asset Securities	-	-	-	-	-	1,870
Cash & Short-Term Investments	834.8	834.8	1,202	754.8	610.9	2,850
Cash Growth	-30.55%	-30.55%	59.26%	23.55%	-78.57%	296.76%
Accounts Receivable	-	13,998	10,248	10,464	8,071	3,486
Other Receivables	-	110.1	477.5	827.1	250.8	166
Receivables	-	14,108	10,726	11,291	8,322	3,652
Inventory	-	22,881	16,435	14,753	16,097	14,862
Prepaid Expenses	-	691.8	500.5	553.2	370.7	357.3
Other Current Assets	-	2,362	1,922	1,748	3,207	4,799
Total Current Assets	-	40,878	30,786	29,100	28,608	26,520
Property, Plant & Equipment	-	33,608	30,711	29,997	39,473	36,472
Long-Term Investments	-	1,272	930.2	963.3	1,184	493.1
Other Intangible Assets	-	-	-	-	1,548	3,238
Long-Term Deferred Tax Assets	-	1,660	1,696	1,230	58.8	-
Other Long-Term Assets	-	311.5	332.9	537.4	348.8	367.2
Total Assets	-	77,729	64,456	61,828	71,220	67,090
Accounts Payable	-	8,799	7,356	6,798	7,064	6,688
Accrued Expenses	-	1,828	1,582	1,418	1,850	1,832
Short-Term Debt	-	11,956	4,305	6,359	4,300	0.2
Current Portion of Long-Term Debt	-	-	-	-	2,000	2,999
Current Portion of Leases	-	151.6	198.3	169.2	149.8	122.8
Current Income Taxes Payable	-	189.1	-	-	-	21.5
Current Unearned Revenue	-	115.6	114.5	112.7	123.6	118.6
Other Current Liabilities	-	1,085	994.2	1,512	1,678	1,027
Total Current Liabilities	-	24,123	14,550	16,369	17,165	12,808
Long-Term Debt	-	-	-	-	-	1,999
Long-Term Leases	-	467.7	628.8	692.3	721.4	715.4
Long-Term Deferred Tax Liabilities	-	-	-	-	-	42.1
Other Long-Term Liabilities	-	972.2	1,005	1,005	958.1	855.3
Total Liabilities	-	25,834	16,274	18,124	18,845	16,420
Common Stock	-	393.1	393.1	393.1	393.1	393.1
Additional Paid-In Capital	-	7,484	7,484	7,484	7,484	7,484
Retained Earnings	-	43,945	40,273	35,687	43,991	41,550
Comprehensive Income & Other	-	87.8	32.4	140.8	507.2	1,243
Total Common Equity	51,909	51,909	48,182	43,705	52,376	50,670
Minority Interest	-	-14.2	-	-	-	-
Shareholders' Equity	51,895	51,895	48,182	43,705	52,376	50,670
Total Liabilities & Equity	-	77,729	64,456	61,828	71,220	67,090
Total Debt	12,575	12,575	5,132	7,220	7,171	5,836
Net Cash (Debt)	-11,740	-11,740	-3,930	-6,465	-6,560	-2,986
Net Cash Per Share	-59.75	-59.73	-19.99	-32.89	-33.37	-15.41
Filing Date Shares Outstanding	196.66	196.56	196.56	196.56	196.56	196.56
Total Common Shares Outstanding	196.66	196.56	196.56	196.56	196.56	196.56
Working Capital	-	16,755	16,236	12,731	11,443	13,712
Book Value Per Share	264.09	264.09	245.12	222.34	266.46	257.78
Tangible Book Value	51,909	51,909	48,182	43,705	50,827	47,432
Tangible Book Value Per Share	264.09	264.09	245.12	222.34	258.58	241.31
Land	-	1,070	1,013	1,017	931.4	1,138
Buildings	-	7,810	7,465	7,068	5,277	5,084
Machinery	-	30,646	28,487	24,961	18,291	16,399
Construction In Progress	-	8,372	5,244	6,013	22,058	19,443
Leasehold Improvements	-	36	18.3	7.9	7.3	-

Updated Feb 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.